Latest studies
- Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCItaly - Active not recruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)
This study is testing a new medicine, zilganersen, for people with Alexander Disease. It aims to see if the medicine is safe and if it can help improve or steady movement abilities. It's a large study, comparing the medicine to a dummy treatment (placebo).
Alexander DiseaseItaly - AuthorisedTherapeutic exploratory (Phase II)
18F-FES PET/MRI for tailoring treatment of luminal A and lobular breast cancer: a phase II trial evaluating the performance of FES PET/MRI in axillary staging
This study is looking at a new type of scan called FES PET/MRI for women with certain types of breast cancer. We want to see if it's better than standard ultrasound at finding cancer in the lymph nodes under the arm.
Primary or advanced breast cancer LumA or ER+ Lobular subtypes.Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)
This study is for people with a certain type of advanced lung cancer that has stopped responding to a previous treatment called osimertinib. It tests a new combination of two drugs, tepotinib and osimertinib, to see if it can shrink tumours.
Lung CancerItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new medicine, AMX0035, for people with Motor Neurone Disease (ALS). It aims to see if the medicine can slow down the disease's progression over 48 weeks, compared to a dummy medicine.
Amyotrophic Lateral Sclerosis (ALS)Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria
This study is looking at a new drug, balcinrenone, given with an existing drug, dapagliflozin (Forxiga), for people with long-term kidney disease and too much protein in their urine. It aims to see if this new combination helps protect the kidneys.
Chronic Kidney Disease and AlbuminuriaItaly - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaItaly - RecruitingPHASE3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
This study looks at an inhaled medicine called treprostinil for people with progressive pulmonary fibrosis. It aims to see if it's safe and effective in slowing down this lung condition over 52 weeks. Half get the medicine, half get a dummy treatment.
Progressive Pulmonary FibrosisInterstitial Lung DiseaseItaly - RecruitingPHASE2, PHASE3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This study looks at switching from one existing medicine, Bulevirtide, to a new one, Brelovitug, for people with long-term Hepatitis D. Researchers want to see if the new medicine is safe and works better.
Chronic Hepatitis DItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immunemediated thrombotic thrombocytopenic purpura
This study is testing a new way to treat a rare blood disorder called TTP. It looks at whether a medicine called Cablivi, along with other treatments, can help people with TTP get better without needing a common but intensive procedure called plasma exchange.
Thrombotic Thrombocytopenic PurpuraItaly - RecruitingPHASE3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
This study is testing a new medicine called iptacopan for people aged 12-60 with a kidney disease called C3 Glomerulopathy (C3G). It aims to see if the medicine is safe and helps improve kidney function compared to a dummy pill.
C3GItaly - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
Metastatic Non-Small Cell Lung CancerItaly - Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
This study looks at how a drug called elafibranor works for people with a rare liver disease called Primary Biliary Cholangitis (PBC) in everyday life. Researchers will check its effects, how safe it is, and how well people tolerate it over about five years.
Primary Biliary CholangitisItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
This study looks at a new medicine called batoclimab for Thyroid Eye Disease (TED). It’s for people who have already taken part in similar batoclimab studies. We want to see how long their eyes stay improved after stopping the medicine and if it helps those who didn't respond before.
Thyroid Eye Disease (TED)Italy - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaItaly - Active not recruitingPHASE3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This study looks at a new combination of medicines, enzalutamide and leuprolide, for men with prostate cancer that hasn't spread but is considered high-risk. The goal is to see how safe and effective this combination is in slowing down the cancer.
Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
This study looks at two medicines, Stelara and Guselkumab, for young people with a type of arthritis called juvenile psoriatic arthritis. It checks how well they work, how safe they are, and how the body handles them.
Juvenile psoriatic arthritisItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
This study is testing a new medicine, batoclimab, for active Thyroid Eye Disease (TED). We want to see if it can help reduce bulging eyes (proptosis) and improve other symptoms, compared to a dummy medicine, in adults with TED.
Thyroid Eye Disease (TED)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
This study is comparing a new medicine, JPB898, to a licensed cancer drug called Opdivo. Both are used with another drug, Yervoy, to treat advanced melanoma, a serious type of skin cancer. The aim is to see if JPB898 works just as well and is as safe as Opdivo.
Advanced (unresectable/metastatic) melanomaItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Giant cell arteritis (GCA)Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment
This study is looking into a new medication (BI 706321) for Crohn's disease. It aims to see if it's safe and effective when taken alongside an existing treatment called Stelara, and how it works in the body.
Crohn`s Disease (CD)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also know as BAX930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)
This study is looking at the long-term safety and helpfulness of a medicine called TAK-755 for people with a rare blood disorder called congenital TTP. It also checks how well TAK-755 prevents TTP episodes in those taking it regularly.
Congenital Thrombotic thrombocytopenic purpura (cTTP)Italy - RecruitingPHASE3
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This study is for people with chronic Hepatitis D (HDV) whose current medicine, bulevirtide, isn't fully controlling the virus. It will test if a new combination of medicines, tobevibart and elebsiran, works better. It's a key step in finding more effective treatments.
Viral HepatitisItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers
This study looks at new ways to treat early-stage triple-negative breast cancer. It tests a drug called nivolumab alongside standard chemotherapy to see if it helps shrink tumours more effectively before surgery. The aim is to improve treatment results for this type of breast cancer.
Early stage triple negative breast cancerItaly - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaItaly - Not yet recruiting
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The LOVE Study is tracking people with fatty liver disease (MASLD, MetALD, ALD) over several years. Its goal is to better understand how these conditions progress and to find simpler ways to check liver health without needing a liver biopsy. This could lead to earlier diagnosis and better care.
Steatotic Liver DiseaseMASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)Steatotic Liver Disease of Mixed Origin (MetALD)ALD - Alcoholic Liver DiseaseItaly - RecruitingPHASE1
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
This study is testing a new medicine, ARGX-119, for adults with a specific type of muscle weakness called DOK7-Congenital Myasthenic Syndrome (CMS). It's looking at how safe the medicine is, if it causes side effects, and if it helps people feel better.
Congenital Myasthenic SyndromeCMSItaly - RecruitingPHASE1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
This study is testing new combinations of anti-cancer medicines for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. It aims to find safe doses and see how well these new combinations work.
B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaItaly - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.
AL AmyloidosisItaly - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)Italy - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
Prostatic NeoplasmsItaly - RecruitingPHASE4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
This study looks at the best time to treat a rare twin pregnancy problem called TRAP sequence. We're comparing treating it early (12-14 weeks) versus later (16-19 weeks) to see which approach works better for the healthy twin. It's a randomised trial, meaning timing is decided by chance.
Twin Reversal Arterial Perfusion SyndromeItaly - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
Lymphoma, Non-HodgkinItaly - Active not recruitingPHASE3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
This study looks at whether fezolinetant can reduce hot flashes in women with breast cancer who are having hormone therapy. These hot flashes are a common side effect, and current treatments like HRT aren't suitable. We want to see if fezolinetant helps more than a dummy pill.
Hot FlashesItaly - RecruitingPHASE4
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
This study looks into why some breast cancers stop responding to treatment. We will examine tissue and blood samples from patients with specific types of breast cancer to understand how the cancer becomes resistant and find new ways to help them.
Breast CancerItaly - RecruitingPHASE3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
This study looks at a new way to treat a specific type of leukaemia (AML) with a gene change called IDH1. It adds a drug called venetoclax to standard treatment (ivosidenib and azacitidine) to see if it works better. It's for patients who can't have strong chemotherapy.
Acute Myeloid LeukemiaItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Had Received Prior Systemic Therapy
This study compares two ways of giving a medicine called Nivolumab for advanced kidney cancer. One way is an injection under the skin, and the other is a drip into a vein. Doctors want to see if the injection works just as well and is safe for patients.
Metastatic Clear Cell Renal Cell CarcinomaItaly - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
This study is looking at a medicine called Simponi for children and teenagers with a gut condition called ulcerative colitis. It wants to see if Simponi can help them feel better and heal their gut, and if it's safe to use.
Ulcerative ColitisItaly - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine called Eftozanermin Alfa (ABBV-621) with standard treatments for people in the UK with multiple myeloma that has come back or isn't responding to other treatments. It's an early-stage study to see how safe and effective the new combination is.
Multiple MyelomaItaly - Active not recruitingNA
Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk
This study looks at a new device, the Omega LAA Occluder, designed to prevent strokes in people with a type of irregular heartbeat called non-valvular atrial fibrillation, especially if they have a high risk of bleeding. It checks how safe and effective the device is.
Non-Valvular Atrial FibrillationItaly - Active not recruitingPHASE3
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This study is testing a new medicine, pembrolizumab, for people in the UK with a type of skin cancer called melanoma that has been removed by surgery but is considered high-risk. It aims to see if the medicine can stop the cancer from coming back.
MelanomaItaly - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
This study looks at new drug combinations for advanced lung cancer. It combines bemcentinib with standard treatments like chemotherapy and immunotherapy. We want to see if these new combinations are safe and effective for people with this type of lung cancer, including those with a specific gene change (STK11 mutation).
Untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, multicenter, open-label study on PREvention of respiratory SEquelae of RSV bronchiolitis in preterm babies (PRESERV)
This study looks at how to help premature babies avoid breathing problems after getting a chest infection called RSV. It compares a medicine called Synagis to no treatment to see if it reduces further breathing issues like wheezing or asthma in their first year.
Respiratory sincizial (RSV) bronchiolitisItaly - Active not recruitingPHASE3
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is testing new drug combinations, pozelimab and cemdisiran, for adults with a muscle-weakening condition called generalised myasthenia gravis (gMG). It looks at how safe these drugs are and how well they help improve muscle function.
Generalized Myasthenia GravisItaly - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for people aged 16-80 with ulcerative colitis that is moderately to severely active. It aims to see how well it works and if it's safe compared to a dummy drug. We hope it could be a new treatment option.
Moderately to Severely Active Ulcerative ColitisItaly - Completed
An international cohort study of wound closure and surgical site infection prevention strategies in abdominal surgery
This study looks at how different ways of closing wounds and preventing infections after tummy surgery affect how well people recover. It aims to improve future surgical care worldwide by gathering information from adults undergoing these operations.
Adult patients (age 18 years and above) undergoing general or colorectal surgical procedures using any type of abdominal incision measuring at least 5 cm (including extraction sites)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
This study is looking at the long-term safety and effectiveness of a new medicine called bimekizumab for adults with moderate to severe hidradenitis suppurativa (HS). It's an extension of an earlier study, helping us understand how well the treatment works and if it causes any side effects over a longer time.
Hidradenitis SuppurativaItaly - Active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
Urothelial CancerItaly